NTLA FY 2018 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

FY 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$30M+16.5% YoY

Gross Profit

-$59M-192.8% margin

Operating Income

-$91M-298.6% margin

Net Income

-$85M-280.4% margin

EPS (Diluted)

$-1.98

Cash Flow

Operating Cash Flow

-$61M

Free Cash Flow

-$68M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$347M

Total Liabilities

$69M

Stockholders' Equity

$278M

Cash & Equivalents

$59M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$30M	$26M	+16.5%
Gross Profit	-$59M	-$42M	-41.3%
Operating Income	-$91M	-$70M	-30.6%
Net Income	-$85M	-$68M	-26.4%